cis-[RuCl₂(1,4-bis(diphenylphosphino)butane)(4,4′-dimethyl-2,2′-bipyridine)] | 1428238-14-5

• 英文名称: cis-[RuCl₂(1,4-bis(diphenylphosphino)butane)(4,4′-dimethyl-2,2′-bipyridine)]
• 英文别名: cis-[RuCl₂(dppb)(4,4′-DMbpy)]；cis-[RuCl2(1,3-bis(diphenylphosphino)propane)(4,4'-dimethyl-2,2'-dipyridyl)]；cis-[RuCl2(dppp)(4,4'-mebipy)]
• CAS: 1428238-14-5
• 化学式: C₃₉H₃₈Cl₂N₂P₂Ru
• 分子量: 768.668
• InChiKey: OQAWWAMCFUFMOO-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  4,4'-二甲基-2,2'-联吡啶 、 cis-[RuCl₂(1,4-bis(diphenylphosphino)butane)(4,4′-dimethyl-2,2′-bipyridine)] 以 二氯甲烷 为溶剂， 反应 24.0h， 以65%的产率得到[RuCl(1-methylimidazole)(1,4-bis(diphenylphosphino)butane)(4,4′-dimethyl-2,2′-bipyridine)]Cl
  参考文献：
  名称：

  钌1-甲基咪唑复合物对非小细胞肺癌的促凋亡活性

  摘要：

  在此，以以下通式获得了含有1-甲基咪唑作为配体的新型钌（II）配合物：[RuCl（1Meim）（dppb）（bpy）] Cl（1），[RuCl（1Meim）（dppb）（4， 4'-DMbpy）] Cl（2），[RuCl（1Meim）（dppb）（5,5'-DMbpy）] Cl（3）和[RuCl（1Meim）（dppb）（phen）] Cl（4）其中，1Meim = 1-甲基咪唑，dppb = 1,4-双（二苯基膦基）丁烷，bpy = 2,2'-联吡啶，4,4'-DMbpy = 4,4'-二甲基-2,2'-联吡啶，5 ，5'-DMbpy = 5,5'-二甲基-2,2'-联吡啶和phen = 1,10-菲咯啉。此外，交换抗衡离子时，获得了包含（1）和（3）阳离子的晶体结构，从而形成了[RuCl（1Meim）（dppb）（bpy）] PF 6（5）和[RuCl（1Meim）（dppb）（5,5'-DMbpy）]

  DOI：

  10.1016/j.jinorgbio.2018.06.008
• 作为产物：
  描述：

  1,3-双(二苯基膦)丙烷 、 cis-[RuCl₂(triphenylphospine)₂(4,4′-methylbipyridine)] 以 二氯甲烷 、 苯 为溶剂， 反应 96.0h， 以90%的产率得到cis-[RuCl₂(1,4-bis(diphenylphosphino)butane)(4,4′-dimethyl-2,2′-bipyridine)]
  参考文献：
  名称：

  New ruthenium(II)/phosphines/diimines complexes: Promising antitumor (human breast cancer) and Mycobacterium tuberculosis fighting agents

  摘要：

  The synthesis and characterization of ruthenium compounds of the type [RuCl2(P)(2)(NN)] [(P)(2) = (PPh3)(2),dppb = 1,4-bis(diphenylphosphino)butano; dppp = 1,3-bis(diphenylphosphino)propane; NN = 5,5'-dimethyl-2,2'dipyridyl (5,5'-mebipy) or 4,4'-dimethyl-2,2'dipyridyl (4,4'-mebipy)] are described. The complexes were characterized using elemental analysis, UVVis and infrared spectroscopies, cyclic voltammetry, and X-ray crystallography. In vitro evaluation of the complexes, using the MTT methodology, revealed their cytotoxic activities in a range of 5.415.7 mu M against the MDA-MB-231 breast tumor cells and showed that, in this case, they are more active than the reference metallodrug cisplatin. The in vitro antimycobacterial activities of the complexes had their Minimum Inhibitory Concentration (MIC) for MTB cell growth measured, by the REMA method. The MICs for these complexes were found to be between 12.5 and 25.0 mu g/mL. The results are comparable with the second line drug cycloserine (MIC = 12.550.0 mu g/mL), commonly used in the treatment of TB. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2013.01.004